Advertisement
Advertisement
WGS
GeneDx Holdings Corp. Class A Common Stock
40.77
USDSponsored
+0.27
+0.67%
May 08, 16:00 UTC -4
Closed
After-Market
40.58
-0.20
-0.48%
WGS Earnings Reports
Positive Surprise Ratio
WGS beat 13 of 19 last estimates.
68%
Next Report
Date of Next Report
Jul 27, 2026
Estimate for Q2 26 (Revenue/ EPS)
$132.05M
/$0.10
Implied change from Q1 26 (Revenue/ EPS)
+29.15%
/-135.71%
Implied change from Q2 25 (Revenue/ EPS)
+28.59%
/-80.00%
GeneDx Holdings Corp. Class A Common Stock earnings per share and revenue
On May 04, 2026, WGS reported earnings of -0.28 USD per share (EPS) for Q1 26, missing the estimate of -0.01 USD, resulting in a -2672.28% surprise. Revenue reached 102.25 million, compared to an expected 114.09 million, with a -10.37% difference. The market reacted with a -49.20% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of 0.10 USD, with revenue projected to reach 132.05 million USD, implying an decrease of -135.71% EPS, and increase of 29.15% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Establishment Labs Holdings Inc.
Report Date
May 06, 2026 For Q1 26
Estimate
-$0.35
Actual
-$0.40
Surprise
-12.80%
Progyny, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.30
Actual
$0.50
Surprise
+63.99%
Omada Health, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.08
Actual
$0.01
Surprise
+112.22%
The Oncology Institute, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.02
Surprise
+74.46%
LifeMD, Inc. Common Stock
Report Date
May 06, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.20
Surprise
+12.85%
SkinHealth Systems Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.05
Surprise
+36.47%
Natera, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.54
Actual
-$0.56
Surprise
-2.36%
Viatris Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.51
Actual
$0.59
Surprise
+15.17%
Charles River Laboratories International, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
$1.96
Actual
$2.06
Surprise
+4.98%
Caris Life Sciences, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
$0.00
Surprise
+100.00%
FAQ
What were GeneDx Holdings Corp. Class A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, GeneDx Holdings Corp. Class A Common Stock reported EPS of -$0.28, missing estimates by -2672.28%, and revenue of $102.25M, -10.37% below expectations.
How did the market react to GeneDx Holdings Corp. Class A Common Stock's Q1 2026 earnings?
The stock price moved down -49.2%, changed from $67.93 before the earnings release to $34.51 the day after.
When is GeneDx Holdings Corp. Class A Common Stock expected to report next?
The next earning report is scheduled for Jul 27, 2026.
What are the forecasts for GeneDx Holdings Corp. Class A Common Stock's next earnings report?
Based on 10
analysts, GeneDx Holdings Corp. Class A Common Stock is expected to report EPS of $0.10 and revenue of $132.05M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement